Immunocore Stock Forecast, Price & News

+0.87 (+2.70 %)
(As of 04/13/2021 01:25 PM ET)
Today's Range
Now: $33.09
50-Day Range
MA: $41.83
52-Week Range
Now: $33.09
Volume1,495 shs
Average Volume117,901 shs
Market Capitalization$1.43 billion
P/E RatioN/A
Dividend YieldN/A
Immunocore Holdings Limited, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company's lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase III clinical trial in patients with previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung, gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising breast, endometrial, ovarian, and small cell lung cancers; and GSK01 that is in a Phase I clinical trial. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Immunocore logo

Industry, Sector and Symbol

Industry Biotechnology
Current SymbolNASDAQ:IMCR
Phone44 1235 438600
Year FoundedN/A



Sales & Book Value

Annual SalesN/A



Market Cap$1.43 billion
Next Earnings DateN/A
OptionableNot Optionable


See More Headlines


Overall MarketRank

1.27 out of 5 stars

Medical Sector

843rd out of 2,016 stocks

Biotechnology Industry

34th out of 144 stocks

Analyst Opinion: 3.3Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
+0.87 (+2.70 %)
(As of 04/13/2021 01:25 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IMCR News and Ratings via Email

Sign-up to receive the latest news and ratings for IMCR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Immunocore (NASDAQ:IMCR) Frequently Asked Questions

Is Immunocore a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immunocore in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Immunocore stock.
View analyst ratings for Immunocore
or view top-rated stocks.

What stocks does MarketBeat like better than Immunocore?

Wall Street analysts have given Immunocore a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Immunocore wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for IMCR?

3 Wall Street analysts have issued 12-month price objectives for Immunocore's stock. Their forecasts range from $40.00 to $65.00. On average, they expect Immunocore's stock price to reach $54.33 in the next year. This suggests a possible upside of 66.2% from the stock's current price.
View analysts' price targets for Immunocore
or view top-rated stocks among Wall Street analysts.

Who are Immunocore's key executives?

Immunocore's management team includes the following people:
  • Dr. Bahija Jallal, CEO & Director (Age 59)
  • Mr. Brian R. Di Donato, CFO & Head of Strategy (Age 54)
  • Ms. Annelise Vuidepot Ph.D., CTO and Head of Pipeline & Platform Research
  • Clayton Robertson, Head of Investor Relations
  • Ms. Lily Hepworth, Gen. Counsel
  • Ms. Debra Nielsen, Head of Communication
  • Ms. Frankie Webster, Chief People Officer
  • Dr. David Berman M.D., Ph.D., Head of R&D (Age 50)
  • Ms. JoAnn Suzich Ph.D., Head of Research
  • Mr. Koustubh Ranade Ph.D., Head of Translational Medicine

Who are some of Immunocore's key competitors?

When did Immunocore IPO?

(IMCR) raised $199 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 8,300,000 shares at $23.00-$25.00 per share. Goldman Sachs, J.P. Morgan and Jefferies acted as the underwriters for the IPO.

What is Immunocore's stock symbol?

Immunocore trades on the NASDAQ under the ticker symbol "IMCR."

When does Immunocore's lock-up period expire?

Immunocore's lock-up period expires on Wednesday, August 4th. Immunocore had issued 9,935,896 shares in its public offering on February 5th. The total size of the offering was $258,333,296 based on an initial share price of $26.00. After the expiration of Immunocore's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

How do I buy shares of Immunocore?

Shares of IMCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Immunocore's stock price today?

One share of IMCR stock can currently be purchased for approximately $32.69.

How much money does Immunocore make?

Immunocore has a market capitalization of $1.41 billion.

How many employees does Immunocore have?

Immunocore employs 291 workers across the globe.

What is Immunocore's official website?

The official website for Immunocore is

How can I contact Immunocore?

The company can be reached via phone at 44 1235 438600.

This page was last updated on 4/13/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.